Clinical Trial Update: A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating pembrolizumab (MK-3475) in blood cancers has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Hodgkin Lymphoma
• Mediastinal B-cell Lymphoma
• Multiple Myeloma
• Myelodysplastic Syndrome
• Non-hodgkin Lymphoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Myelodysplastic Syndrome, Multiple Myeloma | Phase 1 | Status: COMPLETED | Results posted: 2021-07-12